2018
DOI: 10.1056/nejmoa1801993
|View full text |Cite
|
Sign up to set email alerts
|

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Abstract: The use of risk assessment with MRI before biopsy and MRI-targeted biopsy was superior to standard transrectal ultrasonography-guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously. (Funded by the National Institute for Health Research and the European Association of Urology Research Foundation; PRECISION ClinicalTrials.gov number, NCT02380027 .).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

62
1,791
18
43

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 2,385 publications
(2,033 citation statements)
references
References 33 publications
62
1,791
18
43
Order By: Relevance
“…An enhancement of diagnostic accuracy of mpMRI for the detection of highrisk PCa was demonstrated in biopsy-naïve patients [11]. Moreover, the superiority of fusPbx versus sysPbx was shown in a recently published prospective trial evaluating mpMRI and targeted biopsy alone in case of suspicious lesions versus sysPbx alone without the integration of mpMRI [12]. As expected, patients presenting PI-RADS ≥4 lesions showed a higher detection rate of csPCa than patients presenting PI-RADS ≤3 lesions in our cohort.…”
Section: Discussionsupporting
confidence: 77%
See 1 more Smart Citation
“…An enhancement of diagnostic accuracy of mpMRI for the detection of highrisk PCa was demonstrated in biopsy-naïve patients [11]. Moreover, the superiority of fusPbx versus sysPbx was shown in a recently published prospective trial evaluating mpMRI and targeted biopsy alone in case of suspicious lesions versus sysPbx alone without the integration of mpMRI [12]. As expected, patients presenting PI-RADS ≥4 lesions showed a higher detection rate of csPCa than patients presenting PI-RADS ≤3 lesions in our cohort.…”
Section: Discussionsupporting
confidence: 77%
“…As a consequence, most of the current guidelines recommend mpMRI and consecutive targeted biopsy in patients in whom suspicion of PCa remained after a negative biopsy [7][8][9][10]. Previous studies have reported the benefit of MRI/ultrasound-fusion biopsy (fusPbx) in higher detection rates for clinically significant PCa (csPCa) in both biopsy-naïve patients and patients with previously negative prostate biopsy [4][5][6][11][12][13][14][15].…”
Section: Introductionmentioning
confidence: 99%
“…This study demonstrated a 97% accuracy for mpMRI in the diagnosis of prostate cancer. The recently published PRECISION trial which performed an mpMRI on all participants and then randomized those with positive imaging to either targeted biopsy only or standard biopsy found that detection of clinically significant disease was higher in targeted biopsy only group (38% vs. 26%; adjusted difference, 12%; 95% CI, 4%–20%) [19]. This provides level one evidence that MRI and targeted biopsy should be included in the work-up of patients being considered for primary biopsy.…”
Section: Facilitating Targeted Biopsymentioning
confidence: 96%
“…На конгрессе в Коппенгагене были представлены результаты крупного международного многоцентро-вого рандомизированного исследования PRECISION, которые показали преимущества проведения МРТ предстательной железы на начальном этапе диагно-стики РПЖ [14]. Выполнение МРТ предстательной железы и последующей таргетной биопсии подозри-тельных очагов, определенных по МРТ, уменьшает количество ненужных биопсий и вколов, увеличивает выявляемость клинически значимого рака по сравне-нию со стандартной биопсией предстательной железы под контролем трансректального ультразвукового ис-следования.…”
Section: съезды и конференцииunclassified
“…Так-же в стандарты 2-й линии у больных метастатическим раком мочевого пузыря после платиносодержащей химиотерапии вошли еще 2 ингибитора контрольных точек иммунитета -ниволумаб и атезолизумаб, ОНКОУРОЛОГИЯ 2'2018 ТОМ 14 CANCER UROLOGY 2'2018 VOL. 14 …”
unclassified